ArticleHepatology communications2025
Risk and prognosis of HCC in patients with thyroid disease: A nationwide cohort study.
Article in Hepatology communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThyroid hormone levels are associated with HCC in animal studies. We examined HCC risk and prognosis in patients with thyroid disease.
methodsWe included all Danish citizens with a hospital diagnosis for thyroid disease after January 1, 1980, and/or a filled prescription for thyroid medication after 1995. They were 1:10 age-matched, sex-matched, and calendar year-matched with population comparators without thyroid disease diagnoses. All were followed through 2021 for HCC diagnosis and death.
resultsWe included 529,330 patients, followed for up to 42.0 years. Among those with hyperthyroid disease, a current low TSH was associated with lower HCC incidence (adjusted HR: 0.66, 95% CI: 0.29-1.47). Nontoxic goitre was associated with lower mortality after HCC diagnosis (adjusted HR: 0.77, 95% CI: 0.59-1.00), corresponding to an estimated 6 months' increased survival. Those with hypothyroid disease and a high current TSH had a higher HCC incidence (adjusted HR: 2.07, 95% CI: 1.03-4.18).
conclusionsOverall, in this large population-based study, a suppressed TSH level was associated with either lower HCC incidence or longer survival, while an elevated TSH level was associated with higher HCC incidence. Interpreted by TSH level, this suggests that an excess of thyroid hormones protects against HCC and that a deficit in thyroid hormones increases the HCC risk. The therapeutical implications are uncertain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.